Kilitch Drugs India Ltd (BSE: 524500) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹804 Cr, it ranks #1,714 by market cap among the 6,137 Indian listed companies on FinBizNet, and #52 of 86 in Medicinal Chemicals and Botanical Products. At ₹202.24 (as of 25 Oct 2026), the share price is 24.5% below its 52-week high of ₹267.90 and 72.5% above its 52-week low of ₹117.25. The share price is up 8.6% over one year and up 12.3% over three months.
| Current Price | ₹202.24 |
|---|---|
| Market Cap | ₹804 Cr |
| BSE Code | 524500 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 25.4 |
| Return on Equity | 12.36% |
| Return on Assets | 5.56% |
| 52-Week Range | ₹117.25 – ₹267.90 |
| 1-Year Price Change | +8.6% |
| 3-Month Price Change | +12.3% |
| Beta (1Y) | 0.12 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | kilitch.com |
| Revenue | ₹45 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| Net Margin | 4.4% |
| EPS (Basic) | ₹0.83 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional produ
1. Development and Operations of Pharmaceutical Business-This segment engages in the development and operation of pharmaceutical business.
1. Development and Operations of Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Kilitch Drugs India Ltd | ₹804 Cr | 25.4 | 12.36% | ₹45 Cr | +8.6% |
Listed by market capitalisation. Ratios are shown for context only.
Kilitch Drugs India Ltd is trading at ₹202.24, with a market capitalisation of ₹804 Cr.
Kilitch Drugs India Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Kilitch Drugs India Ltd has a P/E of 25.4 and a return on equity of 12.36%.
Kilitch Drugs India Ltd is listed on the BSE under the scrip code 524500.
Kilitch Drugs India Ltd's share price is up 8.6% over one year and up 12.3% over three months. Its 52-week range is ₹117.25 to ₹267.90.
In Q1 FY27, Kilitch Drugs India Ltd reported revenue of ₹45 Cr and net profit of ₹2 Cr, with basic EPS of ₹0.83 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.